Edge Capital Group LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 106,138 shares of the company’s stock after acquiring an additional 2,486 shares during the quarter. Johnson & Johnson makes up 1.6% of Edge Capital Group LLC’s portfolio, making the stock its 11th biggest position. Edge Capital Group LLC’s holdings in Johnson & Johnson were worth $15,802,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Newfound Research LLC bought a new position in Johnson & Johnson during the 3rd quarter valued at $28,000. Islay Capital Management LLC bought a new position in shares of Johnson & Johnson in the 2nd quarter worth about $42,000. FAI Wealth Management lifted its position in shares of Johnson & Johnson by 45.9% in the 2nd quarter. FAI Wealth Management now owns 321 shares of the company’s stock worth $45,000 after buying an additional 101 shares during the last quarter. SeaBridge Investment Advisors LLC lifted its position in shares of Johnson & Johnson by 160.0% in the 2nd quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock worth $46,000 after buying an additional 200 shares during the last quarter. Finally, HWG Holdings LP bought a new position in shares of Johnson & Johnson in the 2nd quarter worth about $49,000. Hedge funds and other institutional investors own 67.44% of the company’s stock.
A number of research analysts have recently issued reports on the stock. Credit Suisse Group raised their price target on shares of Johnson & Johnson from $163.00 to $168.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 14th. Raymond James reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Friday. ValuEngine upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Monday, August 3rd. Cantor Fitzgerald lifted their price objective on shares of Johnson & Johnson from $168.00 to $180.00 and gave the company an “overweight” rating in a research report on Wednesday, October 14th. Finally, Stifel Nicolaus downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, August 19th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $164.93.
Johnson & Johnson stock opened at $146.36 on Friday. The stock has a market cap of $385.30 billion, a price-to-earnings ratio of 23.01, a PEG ratio of 3.04 and a beta of 0.69. The company has a current ratio of 1.48, a quick ratio of 1.24 and a debt-to-equity ratio of 0.51. The company’s 50-day moving average price is $145.51 and its two-hundred day moving average price is $146.57. Johnson & Johnson has a 52 week low of $109.16 and a 52 week high of $157.00.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.98 by $0.22. The company had revenue of $21.08 billion for the quarter, compared to analysts’ expectations of $20.15 billion. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The business’s revenue was up 1.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.12 EPS. Research analysts expect that Johnson & Johnson will post 7.99 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a $1.01 dividend. The ex-dividend date of this dividend is Monday, November 23rd. This represents a $4.04 annualized dividend and a dividend yield of 2.76%. Johnson & Johnson’s dividend payout ratio is currently 46.54%.
In other news, EVP Kathryn E. Wengel sold 16,115 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total value of $2,473,974.80. Following the transaction, the executive vice president now owns 66,658 shares of the company’s stock, valued at approximately $10,233,336.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.27% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Further Reading: Cash Flow Analysis in Stock Selection
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.